This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kurt, T. D.
Right arrow Articles by Hoover, E. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kurt, T. D.
Right arrow Articles by Hoover, E. A.

 Previous Article  |  Next Article 

Journal of Virology, September 2007, p. 9605-9608, Vol. 81, No. 17
0022-538X/07/$08.00+0     doi:10.1128/JVI.00635-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Efficient In Vitro Amplification of Chronic Wasting Disease PrPRES{triangledown}

Timothy D. Kurt,1 Matthew R. Perrott,1 Carol J. Wilusz,1 Jeffrey Wilusz,1 Surachai Supattapone,2 Glenn C. Telling,3 Mark D. Zabel,1 and Edward A. Hoover1*

Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado,1 Department of Biochemistry, Dartmouth Medical School, Hanover, New Hampshire,2 Department of Molecular Biology and Genetics, University of Kentucky, Lexington, Kentucky3

Received 25 March 2007/ Accepted 30 May 2007


arrow
ABSTRACT
 
Chronic wasting disease (CWD) of cervids is associated with conversion of the normal cervid prion protein, PrPC, to a protease-resistant conformer, PrPCWD. Here we report the use of both nondenaturing amplification and protein-misfolding cyclic amplification (PMCA) to amplify PrPCWD in vitro. Normal brains from deer, transgenic mice expressing cervid PrPC [Tg(cerPrP)1536 mice], and ferrets supported amplification. PMCA using normal Tg(cerPrP)1536 brains as the PrPC substrate produced >6.5 x 109-fold amplification after six rounds. Highly efficient in vitro amplification of PrPCWD is a significant step toward detection of PrPCWD in the body fluids or excreta of CWD-susceptible species.


arrow
TEXT
 
Chronic wasting disease (CWD) of cervids is a transmissible spongiform encephalopathy (TSE), akin to sheep scrapie and bovine spongiform encephalopathy. TSE pathogenesis is associated with refolding of the normal prion protein, PrPC, into a partially protease resistant isomer termed PrPRES (2, 15, 17). A remarkable feature of CWD among prion diseases is its horizontal transmission in nature (12), suggesting that PrPC conversion is highly efficient in this TSE and perhaps is associated with the presence of infectious prions in the body fluids of deer (10). CWD is also transmissible to and pathogenic in ferrets (1) and transgenic mice expressing normal cervid PrPC (3, 8, 11).

Raymond and colleagues (18) first demonstrated the conversion of cervid PrPC to PrPRES in vitro. Nondenaturing amplification without the use of radiolabeling (7, 9) further contributed to understanding of the mechanisms of PrPC-to-PrPRES conversion due to its directness and technical simplicity. Soto, Castilla, and colleagues (5, 6, 21) greatly extended the process and power of in vitro PrPRES amplification by developing protein-misfolding cyclic amplification (PMCA). In PMCA, normal brain homogenates (NBH) supply PrPC, which, upon addition of an infected brain homogenate, is refolded into the protease-resistant isoform, PrPRES. Breakage of aggregates by use of sonic bursts releases the newly formed PrPRES and extends the enciphering process (19, 20, 22).

To begin to address the mechanisms of PrPC-to-PrPRES conversion in CWD and to enhance the sensitivity of CWD prion (PrPCWD) detection in deer, we developed two in vitro amplification assays: nondenaturing amplification patterned after the technique of Lucassen et al. (9) and serial PMCA modeled after the method of Soto and colleagues (19, 21). Here we report amplification using CWD-negative brain homogenates from white-tailed deer (Odocoileus virginianus), cervid PrP transgenic mice [Tg(cerPrP)1536 mice] (3), and ferrets (Mustela putorius furo), a species shown to be susceptible to CWD infection in vivo (1).

Preparation of tissue homogenates. Whole brains were removed rapidly after sacrifice from CWD-free animals and were immediately frozen in liquid nitrogen. For PMCA experiments, animals were perfused at death with phosphate-buffered saline (PBS) containing 5 mM EDTA. NBH were prepared by homogenization of brains with a glass Dounce homogenizer (Kontes) or glass beads (FastPrep; set at 6.5 for 45 s; Qbiogene, Irvine, CA) in 9 volumes of cold PBS (nondenaturing experiments) or PBS with Triton X-100, 5 mM EDTA, 150 mM NaCl, and 0.05% saponin (Sigma) plus CompleteMini protease inhibitors (Roche) to a final concentration of 10% (wt/vol) (PMCA experiments). NBH were centrifuged at 200 x g for 30 s (nondenaturing experiments) or 2,000 x g for 1 min (PMCA experiments), and the supernatants were removed and frozen at –70°C for use. A CWD-positive sample of deer origin (D10; provided by Michael Miller, Colorado Division of Wildlife, Fort Collins) consisted of a brain from an experimentally infected mule deer and was prepared as a 10% (wt/vol) homogenate. A ferret-adapted CWD-positive sample (CSU-1) was composed of the pooled brains of three experimentally infected ferrets prepared as a 20% (wt/vol) homogenate. These ferrets exhibited typical CWD symptoms and were euthanized 4.5 to 5 months postinoculation (M. R. Perrott et al., unpublished data).

In vitro PrPCWD amplification. For nondenaturing experiments, D10 was diluted 1:200 and CSU-1 was diluted 1:40 in PBS plus 1% Triton X-100 to final dilutions of 1:2,000 and 1:200, respectively, relative to whole brain. For amplification, 50 µl of each was mixed with 50 µl of homologous-species NBH. Dilutions of D10 or CSU-1 equivalent to specific multiples of input were frozen, not amplified, for use in quantification (Fig. 1). Amplified samples were incubated at 37°C with continuous shaking in a Thermomixer R (Invitrogen). Afterwards, all samples were digested for 1 h at 37°C with 50 µg/ml (deer tissues) or 30 µg/ml (ferret tissues) proteinase K (PK; Invitrogen), and 40 µl of each sample was boiled with 15 µl lithium dodecyl sulfate (Invitrogen). For PMCA, D10 was diluted to a final concentration of 1:1,000 in NBH, with serial 1:3 dilutions in NBH to a final dilution of 1:6,561,000. Sixty microliters of each dilution was incubated at 37°C in a Misonix (Farmingdale, NY) sonicator 3000 containing 160 ml water, programmed for 96 cycles of a 40-s pulse (at power level 7) plus 30 min of incubation. After 48 h of sonication/incubation (one round), 8.25 µl of each sample was brought to 0.875% sodium dodecyl sulfate and digested with 150 µg/ml PK at 37°C for 20 min and at 45°C for 10 min. All samples (final volume, 15 µl) were then boiled with 5 µl lithium dodecyl sulfate.


Figure 1
View larger version (44K):
[in this window]
[in a new window]

  		FIG. 1. Deer and ferret NBH support amplification. (A) (Top panel) Deer NBH was used to amplify PrPCWD from an infected mule deer (D10). (Bottom panel) Ferret NBH was used to amplify PrPCWD from CSU-1, a ferret-adapted CWD strain. 8x, 4x, and 2x, dilutions of D10 NBH equivalent to eight-, four-, and twofold more material, respectively, than the input, represented by "0 h"; N, NBH subjected to the amplification protocol and digested with PK; PK+ and PK–, positive brain either digested or not digested with PK, respectively. (B) PMCA applied to amplify PrPCWD in deer NBH. Lanes 1 and 2, undigested NBH diluted 1:250 and 1:500, respectively, after sonication/incubation; lanes 3 to 5, serial 1:3 dilutions of D10 in NBH, starting at 1:1,000 relative to whole brain, not amplified; lanes 6 to 11, continuing serial 1:3 dilutions of D10 in NBH, from 1:27,000 to 1:6,561,000, after 48 h of PMCA; lane 12, NBH subjected to sonication/incubation, followed by digestion with PK.

Electrophoresis and immunoblotting. For nondenaturing experiments, samples were loaded onto 4 to 12% gels (Invitrogen) and transferred to polyvinylidene difluoride membranes (Millipore) using Bio-Rad equipment, and the membranes were blocked using a solution of 6% milk powder (Carnation) for >1 h. Membranes were then incubated for 1 h in 2 µg/ml monoclonal antibody Bar224 (a generous gift from Jacques Grassi, CEA/Saclay, France) diluted 1:10,000 in the blocking solution described above. Membranes were rinsed in Tris-buffered saline plus 0.2% Tween 20 and were incubated for 45 min in horseradish peroxidase-labeled goat anti-mouse immunoglobulin G as a secondary antibody (Jackson Laboratories) diluted 1:20,000 in blocking solution. They were rinsed again before immersion in ECL-plus chemiluminescent reagents (Amersham), exposure to BioMax film (Kodak, Rochester, NY), and development using a Mini Medical/90 film processor (AFP Imaging). Only films clearly below saturation level were used for quantification in Adobe Photoshop. For PMCA experiments, samples (processed as described above) were loaded onto 12% gels; transfer and blocking steps were identical to those described above. Membranes were incubated for >2 h with Bar224 that had been conjugated directly to horseradish peroxidase and diluted 1:20,000 in blocking solution. Membranes were then washed 30 times in distilled H2O plus 0.2% Tween 20, for 5 min each time, before the application of ECL-plus. Membranes from PMCA experiments were analyzed using a digital Gel-Doc system (Fujifilm) with automated detection of saturation limits; bands were quantified using ImageGauge (Fujifilm).

Brain substrates from deer and ferrets support noncyclic amplification of PrPCWD. To determine whether deer brain homogenates could support PrPCWD amplification, we mixed 10% (wt/vol) NBH from uninfected white-tailed deer with an equal volume of a diluted brain homogenate from a CWD-infected mule deer (D10) shown to be infectious to both Tg(cerPrP)1536 mice and white-tailed deer in vivo (3, 10). At specified times during amplification, samples were removed and frozen for subsequent analysis by Western blotting. This nondenaturing protocol consistently produced ~3-fold PrPCWD amplification by 8 h (Fig. 1A, top panel). Interestingly, most of the conversion activity occurred within the first 2 to 4 h of incubation.

As part of ongoing CWD species barrier studies, we have developed ferrets as an alternate animal model of CWD infection (C. J. Sigurdson et al., unpublished data; Perrott et al., unpublished), extending the work of Bartz et al. (1), who first reported ferret susceptibility to CWD. To expand this work to in vitro amplification, we spiked CWD-infected ferret brains into NBH made from uninfected normal ferret brain; this resulted in consistent ~5- to 10-fold PrPCWD amplification over a 12-h period (Fig. 1A, bottom panel). This result was notable in achieving higher amplification efficiency than was obtained with deer NBH and in demonstrating amplification of PrPCWD in a CWD-susceptible noncervid species.

Cyclic amplification of PrPCWD in deer and Tg(cerPrP)1536 mouse brains. To increase the amount of PrPCWD generated by in vitro amplification, we next applied the PMCA protocol to amplify PrPCWD from a mule deer. White-tailed deer NBH was spiked with the CWD-positive D10 deer brain homogenate, the same infectious PrPCWD source that was used in the nondenaturing experiments described above. After incubation with intermittent sonication, detection of PrPCWD by Western blotting revealed a final amplification yield of ~6- to 27-fold, as calculated by the band intensity relative to nonamplified, starting dilutions (Fig. 1B). Serial amplification, in which amplified material is diluted into fresh NBH and subjected to additional cycles of PMCA to increase the overall yield, was unsuccessful using deer NBH, presumably due to the sporadic, low amplification yields (i.e., ≤10-fold) of these experiments.

To improve upon these results, we prepared NBH from pooled whole brains of Tg(cerPrP)1536 mice (3), animals in which the amino acid sequence of PrPC is identical to that in white-tailed deer. Semiquantitative estimation of PrPC levels in Tg(cerPrP)1536 mouse brain versus deer brain homogenates by Western blot analysis revealed ~5- to 8-fold greater PrPC expression in the brain tissues of these mice (Fig. 2A and B). When Tg(cerPrP)1536 NBH was diluted 1:4 into PrP0/0 brain (4), to approximate the PrPC concentration in deer, the amplification yield (Fig. 2C) was very similar to that obtained using deer NBH (Fig. 1B). As might be anticipated, when Tg(cerPrP)1536 mouse NBH was diluted 1:8 into PrP0/0 brain, no amplification was detected (Fig. 2C).


Figure 2
View larger version (34K):
[in this window]
[in a new window]

  		FIG. 2. Semiquantitative estimation of PrPC in brains of deer versus Tg(cerPrP)1536 mice and effect of PrPC concentration on PMCA. (A) Serial 1:2 dilutions of NBH were analyzed by Western blotting. Lanes 1 to 5, deer NBH; lanes 6 to 10, Tg(cerPrP)1536 NBH. Molecular weights, in thousands (K), are indicated on the left. (B) Western blot bands, the size and density of which correspond to the amount of PrPC, were quantified and plotted for comparison. (C) Tg(cerPrP)1536 NBH was diluted 1:4 (lanes 5 to 7 and 11) or 1:8 (lanes 8 to 10) in a PrP0/0 brain for PMCA. Lane 1, undigested NBH diluted 1:250; lanes 2 to 4, serial 1:3 dilutions of D10 in NBH, starting at 1:1,000 relative to whole brain, not amplified; lanes 5 to 7 and 8 to 10, D10 diluted 1:27,000, 1:81,000, and 1:243,000, respectively, after PMCA; lane 11, NBH subjected to sonication/incubation, followed by digestion with PK.

Following these results, we substituted Tg(cerPrP)1536 mouse NBH for deer NBH entirely, and the PMCA yield increased ~20 times, to more than 200-fold per round (Fig. 3, round 1). Moreover, serial PMCA, diluting amplified material into fresh Tg(cerPrP)1536 NBH for each successive round, resulted in a yield of >6.56 x 109-fold after just six rounds (Fig. 3, round 6). Theoretically, serial PMCA attaining ~200-fold increases at each round would result in a ~6.4 x 1013-fold total increase after six rounds. To maintain characteristic Western blot PrPCWD signals, we diluted samples less than 200-fold at each round (Fig. 3), resulting in a slightly lower final yield. More importantly, the Tg(cerPrP)1536 NBH served as a very efficient substrate for PrPCWD amplification relative to deer NBH, likely reflecting the higher expression of PrPC relative to that in deer.


Figure 3
View larger version (25K):
[in this window]
[in a new window]

  		FIG. 3. Amplification of PrPCWD in Tg(cerPrP)1536 mouse NBH by PMCA. (Left panels) Rounds 1 to 3. Lanes 1 and 2, undigested NBH diluted 1:250 and 1:500, respectively, after sonication/incubation; lanes 3 to 5, serial 1:3 dilutions of D10 in NBH, starting at 1:1,000 relative to whole brain, not amplified; lanes 6 to 11, continuing serial 1:3 dilutions of D10 in NBH, from 1:27,000 to 1:6,561,000, after 48 h of PMCA; lane 12, unspiked NBH subjected to sonication/incubation and digestion with PK. For rounds 2 and 3, samples from lanes 6 to 11 from the preceding round were diluted 1:10 into fresh NBH and subjected to another 48 h of PMCA, followed by immunoblotting. (Right panels) Rounds 4 to 6. Lane 1, undigested NBH diluted 1:250 after sonication/incubation; lanes 2 to 11, each sample either amplified by PMCA or not, as indicated; lane 12, NBH subjected to sonication/incubation, followed by digestion with PK. For round 4, material from lanes 7 to 11 from the previous round was diluted 1:100 into fresh Tg(cerPrP)1536 mouse NBH and subjected to PMCA. For rounds 5 to 6, material from lanes 3, 5, 7, 9, and 11 was diluted 1:100 in fresh Tg(cerPrP)1536 mouse NBH and subjected to PMCA.

Previously, Raymond and colleagues (18) observed highly efficient conversion of white-tailed deer PrPC by using mule deer-derived PrPCWD as a spike source in a cell-free conversion system employing radiolabeled PrPC as a substrate. Therefore, we examined further the premise that in PMCA, the more efficient amplification in Tg(cerPrP)1536 mouse versus deer NBH was due principally to the substrate PrPC concentration as opposed to other factors such as higher levels of conversion-enhancing cofactors (e.g., single-stranded RNA [7] or heparan sulfate proteoglycan [23]) in mouse brains. We added increasing concentrations of PrP0/0 mouse NBH to the deer NBH; this did not improve the amplification yield (data not shown). We then evaluated the addition of deer NBH to Tg(cerPrP)1536 NBH; this did not inhibit amplification in comparison to addition of an equivalent amount of a PrP0/0 mouse brain, making the presence of inhibitory factors in deer brains less likely (Fig. 4). The low amplification efficiency obtained by using deer NBH is unlikely to be due to a species barrier between mule deer (our PrPCWD source) and white-tailed deer (our NBH source). These two cervid species have identical PrPC amino acid sequences and brain PrP glycosylation patterns, variables that have been shown to affect in vitro conversion (13, 16). The presence of serine versus glycine at PrPC position 96 in white-tailed deer has been associated with greater resistance to CWD in white-tailed deer and transgenic mice (11, 14). All white-tailed deer used for NBH in these studies were of the more susceptible 96G PrP genotype. Thus, efficient in vitro amplification of PrPCWD by PMCA appears to reflect the higher concentration of PrPC in Tg(cerPrP)1536 mouse brains versus deer brains.


Figure 4
View larger version (17K):
[in this window]
[in a new window]

  		FIG. 4. A deer brain homogenate does not inhibit PMCA in a Tg(cerPrP)1536 NBH. A Tg(cerPrP)1536 NBH was diluted 50:50 with either deer (lanes 5 to 7 and 11) or PrP0/0 (lanes 8 to 10) NBH for PMCA. Lane 1, undigested NBH diluted 1:250; lanes 2 to 4, serial 1:3 dilutions of D10 in NBH, starting at 1:1,000 relative to whole brain, not amplified; lanes 5 to 7 and 8 to 10, D10 diluted 1:27,000, 1:81,000, and 1:243,000, respectively, after PMCA; lane 11, NBH subjected to sonication/incubation followed by digestion with PK.

In summary, we report efficient amplification of PrPCWD by using brain substrates from Tg(cerPrP)1536 mice. The magnitude of PrPCWD conversion obtained by serial PMCA may make possible in vitro detection of PrPCWD in the body fluids and excreta of infected animals. These studies have been initiated.


arrow
ACKNOWLEDGMENTS
 
We thank especially David Osborn, Sallie Dahmes, Charles Weissman, Candace Mathiason, Gary Mason, Bruce Pulford, Jeannette Hayes-Klug, and Sheila Hayes for valuable resources and help with multiple aspects of these studies.

This work was supported by contract NIH-NIAID-N01-A1-25491 from the U.S. Based Collaboration in Emerging Viral and Prion Diseases program and grant R21-AI-58979 from the National Institute of Allergy and Infectious Diseases, National Institutes of Health.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523. Phone: (970) 491-7587. Fax: (970) 491-0523. E-mail: edward.hoover{at}colostate.edu Back

{triangledown} Published ahead of print on 6 June 2007. Back


arrow
REFERENCES
 
    1
  1. Bartz, J. C., R. F. Marsh, D. I. McKenzie, and J. M. Aiken. 1998. The host range of chronic wasting disease is altered upon passage in ferrets. Virology 251:297-301.[CrossRef][Medline]
    2. 2
  2. Bolton, D. C., M. P. McKinley, and S. B. Prusiner. 1982. Identification of a protein that purifies with the scrapie prion. Science 218:1309-1311.[Abstract/Free Full Text]
    3. 3
  3. Browning, S. R., G. L. Mason, T. Seward, M. Green, G. A. J. Eliason, C. Mathiason, M. W. Miller, E. S. Williams, E. A. Hoover, and G. C. Telling. 2004. Transmission of prions from mule deer and elk with chronic wasting disease to transgenic mice expressing cervid PrP. J. Virol. 78:13345-13350.[Abstract/Free Full Text]
    4. 4
  4. Bueler, H., M. Fischer, Y. Lang, H. Bleuthmann, H. P. Lipp, S. J. DeArmond, S. B. Prusiner, M. Aguet, and C. Weissman. 1992. Normal development and behavior of mice lacking the neuronal cell-surface PrP protein. Nature 356:577-582.[CrossRef][Medline]
    5. 5
  5. Castilla, J., P. Saa, C. Hetz, and C. Soto. 2005. In vitro generation of infectious scrapie prions. Cell 121:195-206.[CrossRef][Medline]
    6. 6
  6. Castilla, J., P. Saa, and C. Soto. 2005. Detection of prions in blood. Nat. Med. 11:982-985.[Medline]
    7. 7
  7. Deleault, N. R., R. W. Lucassen, and S. Supattapone. 2003. RNA molecules stimulate prion conversion. Nature 425:717-720.[CrossRef][Medline]
    8. 8
  8. Kong, Q., S. Huang, W. Zou, D. Vanegas, M. Wang, D. Wu, J. Yuan, M. Zheng, H. Bai, H. Deng, K. Chen, A. L. Jenny, K. O'Rourke, E. D. Belay, L. B. Schonberger, R. B. Petersen, M. S. Sy, S. G. Chen, and P. Gambetti. 2005. Chronic wasting disease of elk: transmissibility to humans examined by transgenic mouse models. J. Neurosci. 25:7944-7949.[Abstract/Free Full Text]
    9. 9
  9. Lucassen, R., K. Nishina, and S. Supattapone. 2003. In vitro amplification of protease-resistant prion protein requires free sulfhydryl groups. Biochemistry 42:4127-4135.[CrossRef][Medline]
    10. 10
  10. Mathiason, C. K., J. G. Powers, S. J. Dahmes, D. A. Osborn, K. V. Miller, R. J. Warren, G. L. Mason, S. A. Hayes, J. Hayes-Klug, D. M. Seelig, M. A. Wild, L. L. Wolfe, T. R. Spraker, M. W. Miller, C. J. Sigurdson, G. C. Telling, and E. A. Hoover. 2006. Infectious prions in the saliva and blood of deer with chronic wasting disease. Science 314:133-136.[Abstract/Free Full Text]
    11. 11
  11. Meade-White, K., B. Race, M. Trifilo, A. Bossers, C. Favara, R. Lacasse, M. Miller, E. Williams, M. Oldstone, R. Race, and B. Chesebro. 2007. Resistance to chronic wasting disease (CWD) in transgenic mice expressing a naturally occurring allelic variant of deer prion protein. J. Virol. 81:4533-4539.[Abstract/Free Full Text]
    12. 12
  12. Miller, M. W., and E. S. Williams. 2003. Prion disease: horizontal prion transmission in mule deer. Nature 425:35-36.[CrossRef][Medline]
    13. 13
  13. Nishina, K. A., N. R. Deleault, S. P. Mahal, I. Baskakov, T. Luhrs, R. Riek, and S. Supattapone. 2006. The stoichiometry of host PrPC glycoforms modulates the efficiency of PrPSc formation in vitro. Biochemistry 45:14129-14139.[CrossRef][Medline]
    14. 14
  14. O'Rourke, K. I., T. R. Spraker, L. K. Hamburg, T. E. Besser, K. A. Brayton, and D. P. Knowles. 2004. Polymorphisms in the prion precursor functional gene but not the pseudogene are associated with susceptibility to chronic wasting disease in white-tailed deer. J. Gen. Virol. 85:1339-1346.[Abstract/Free Full Text]
    15. 15
  15. Pan, K. M., M. Baldwin, J. Nguyen, M. Gasset, A. Serban, D. Groth, I. Mehlhorn, Z. Huang, R. J. Fletterick, F. E. Cohen, and S. B. Prusiner. 1993. Conversion of {alpha}-helices into ß-sheet features in the formation of the scrapie prion proteins. Proc. Natl. Acad. Sci. USA 90:10962-10966.[Abstract/Free Full Text]
    16. 16
  16. Priola, S. A., and V. A. Lawson. 2001. Glycosylation influences cross-species formation of protease-resistant prion protein. EMBO J. 20:6692-6699.[CrossRef][Medline]
    17. 17
  17. Prusiner, S. B. 1998. Prions. Proc. Natl. Acad. Sci. USA 95:13363-13383.[Abstract/Free Full Text]
    18. 18
  18. Raymond, G. J., A. Bossers, L. D. Raymond, K. I. O'Rourke, L. E. McHolland, P. K. Bryant III, M. W. Miller, E. S. Williams, M. Smits, and B. Caughey. 2000. Evidence of a molecular barrier limiting susceptibility of humans, cattle and sheep to chronic wasting disease. EMBO J. 19:4425-4430.[CrossRef][Medline]
    19. 19
  19. Saa, P., J. Castilla, and C. Soto. 2004. Cyclic amplification of protein misfolding and aggregation, p. 53-65. In E. M. Sigurdsson (ed.), Amyloid proteins: methods and protocols. New York University School of Medicine, New York, NY.
    20. 20
  20. Saborio, G. P., C. Soto, R. J. Kascsak, E. Levy, R. Kascsak, D. A. Harris, and B. Frangione. 1999. Cell-lysate conversion of prion protein into its protease-resistant isoform suggests the participation of a cellular chaperone. Biochem. Biophys. Res. Commun. 258:470-475.[CrossRef][Medline]
    21. 21
  21. Saborio, G. P., B. Permanne, and C. Soto. 2001. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 411:810-813.[CrossRef][Medline]
    22. 22
  22. Soto, C., L. Anderes, S. Suardi, F. Cardone, J. Castilla, M. J. Frossard, S. Peano, P. Saa, L. Limido, M. Carbonatto, J. Ironside, J. M. Torres, M. Pocchiari, and F. Tagliavini. 2005. Pre-symptomatic detection of prions by cyclic amplification of protein-misfolding. FEBS Lett. 579:638-642.[CrossRef][Medline]
    23. 23
  23. Wong, C., L. W. Xiong, M. Horiuchi, L. Raymond, K. Wehrly, B. Chesebro, and B. Caughey. 2001. Sulfated glycans and elevated temperature stimulate PrPSc-dependent cell-free formation of protease-resistant prion protein. EMBO J. 20:377-386.[CrossRef][Medline]

Journal of Virology, September 2007, p. 9605-9608, Vol. 81, No. 17
0022-538X/07/$08.00+0     doi:10.1128/JVI.00635-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Maddison, B. C., Baker, C. A., Rees, H. C., Terry, L. A., Thorne, L., Bellworthy, S. J., Whitelam, G. C., Gough, K. C. (2009). Prions Are Secreted in Milk from Clinically Normal Scrapie-Exposed Sheep. J. Virol. 83: 8293-8296 [Abstract] [Full Text]  
  • Thorne, L., Terry, L. A. (2008). In vitro amplification of PrPSc derived from the brain and blood of sheep infected with scrapie. J. Gen. Virol. 89: 3177-3184 [Abstract] [Full Text]  
  • Harrington, R. D., Baszler, T. V., O'Rourke, K. I., Schneider, D. A., Spraker, T. R., Liggitt, H. D., Knowles, D. P. (2008). A species barrier limits transmission of chronic wasting disease to mink (Mustela vison). J. Gen. Virol. 89: 1086-1096 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kurt, T. D.
Right arrow Articles by Hoover, E. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kurt, T. D.
Right arrow Articles by Hoover, E. A.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»